The FDA has issued a warning about adolescents who use Strattera (atomoxetine) for ADD/ADHD. Several studies have indicated that there may be an increased risk of suicidal thinking or attempts in teenagers taking the drug. The review is part of a larger effort and concern about the risks of psychiatric drugs in teenagers.
Children and adolescents taking Strattera should be closely monitored for agitation, irritability, suicidal thinking or behaviors, or any other unusual changes in behavior, particularly when starting the medication or making any changes in dose. Parents should closely watch their children for these signs and notify their doctor immediately if they occur. For more information, see the FDA website below.
